Industry

Unlocking the Potential of Autologous Cell & Gene Therapy Through Digital Transformation

Unlocking the Potential of Autologous Cell & Gene Therapy Through Digital Transformation

Autologous and personalized cell and gene therapies (CGTs) are at the frontier of modern medicine, offering potential cures for previously untreatable conditions. However, scaling these therapies presents complex challenges distinct from traditional pharmaceuticals. Manufacturing requires managing multiple small, patient-specific batches, leading to issues such as high costs, time-sensitive processes, and regulatory scrutiny, alongside demands for precise data management and traceability. To address these challenges, organizations are adopting digital strategies that include intelligent automation, real-time monitoring, and AI-driven process optimization. Emerson’s white paper, “Digital Excellence for Advanced Therapies,” provides valuable insights into digital transformation, showcasing methods to build scalable and compliant CGT manufacturing environments, reduce batch variability, and accelerate delivery to patients, ensuring effective regulatory compliance.

read more

Keep Up to Date With the Latest News and Updates

Follow Us

We invite you to follow us on Facebook, LinkedIn, Twitter and YouTube to stay up to date on the latest news, events and innovations that will help you face and solve your toughest challenges.

Do you want to reuse or translate content?

Just post a link to the entry and send us a quick note so we can share your work. Thank you very much.

Our Global Community

Emerson Exchange 365

The opinions expressed here are the personal opinions of the authors. Content published here is not read or approved by Emerson before it is posted and does not necessarily represent the views and opinions of Emerson.

PHP Code Snippets Powered By : XYZScripts.com